Clearmind Medicine
CMND
3 hedge funds and large institutions have $175K invested in Clearmind Medicine in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
200% more funds holding
Funds holding: 1 → 3 (+2)
1.92% more ownership
Funds ownership: 2.92% → 4.84% (+1.9%)
33% less capital invested
Capital invested by funds: $260K → $175K (-$85.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.3K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$29.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.5K |
Top Sellers
CMND Hedge Fund Activity: Q1 2024 in Review
3 of the 6,962 institutional investors tracked by Wall St. Rank reported a position in Clearmind Medicine (CMND) for Q1 2024, worth a combined $175K — down 33% from $260K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CMND positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $34.3K.
- 3 institutional investors held Clearmind Medicine (CMND) as of Q1 2024, up from 1 in Q4 2023.
- Funds reported $175K of Clearmind Medicine stock for Q1 2024, down 33% quarter-over-quarter.
- 2 funds opened new Clearmind Medicine positions in Q1 2024 and 0 closed out, a net change of +2 holders.
- The largest Clearmind Medicine buyer in Q1 2024 was Susquehanna International Group, an estimated $34.3K added.
Based on aggregated 13F filings for Q1 2024.